GRI Bio Inc
Research GRI Bio Inc (GRI) on Bullrun: market cap USD 3.29M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerGRI
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 3.29M
- Financial periodFY2025
- Net income-USD 11.96M
- Free cash flow-USD 10.19M
Valuation Snapshot
latest market cap is USD 3.29M.
About GRI Bio Inc
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis.
Frequently asked questions
What is GRI Bio Inc's market cap?
GRI Bio Inc's market capitalization is USD 3.29M.
What does GRI Bio Inc do?
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States.